Pre-made Ontuxizumab benchmark antibody ( Whole mAb, anti-CD248 therapeutic antibody, Anti-CD164L1/TEM1 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Ontuxizumab biosimilar, Whole mAb, Anti-CD248 Antibody: Anti-CD164L1/TEM1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Ontuxizumab is a humanized rabbit monoclonal antibody designed for the treatment of cancer. It binds to endosialin (TEM1 or CD248).

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-405-1mg	1mg	3090
GMP-Bios-ab-405-10mg	10mg	Inquiry
GMP-Bios-ab-405-100mg	100mg	Inquiry
GMP-Bios-ab-405-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Ontuxizumab biosimilar, Whole mAb, Anti-CD248 Antibody: Anti-CD164L1/TEM1 therapeutic antibody
INN Name	Ontuxizumab
Target	CD248
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2013
Year Recommended	2014
Companies	Ludwig Institute for Cancer Research;Morphotek;National Cancer Institute (USA)
Conditions Approved	na
Conditions Active	Colorectal cancer;Malignant melanoma;Soft tissue sarcoma
Conditions Discontinued	Lymphoma;Solid tumours
Development Tech	na